The pharmacogenomics wave does not seem to have hit European shores just yet: Venture capitalists there have a tepid interest in local SNP and pharmacogenomic startups, and companies there anxious about private-equity financing are in for a long, hot summer, most experts agree. It didn t have to be this way. Subscribe. (https://www.snptech.com/subscribe.htmtarget=_blank)

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.